Responsive Exosome Nano‐bioconjugates for Synergistic Cancer Therapy

Exosomes hold great potential in therapeutic development. However, native exosomes usually induce insufficient effects in vivo and simply act as drug delivery vehicles. Herein, we synthesize responsive exosome nano‐bioconjugates for cancer therapy. Azide‐modified exosomes derived from M1 macrophages...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition Vol. 59; no. 5; pp. 2018 - 2022
Main Authors: Nie, Weidong, Wu, Guanghao, Zhang, Jinfeng, Huang, Li‐Li, Ding, Jingjing, Jiang, Anqi, Zhang, Yahui, Liu, Yanhong, Li, Jingchao, Pu, Kanyi, Xie, Hai‐Yan
Format: Journal Article
Language:English
Published: Germany Wiley Subscription Services, Inc 27.01.2020
Edition:International ed. in English
Subjects:
Antibodies
Cancer
Cancer therapies
Cell surface
Drug delivery
Drug delivery systems
Exosomes
Exosomes - metabolism
Humans
immunotherapy
Immunotherapy - methods
Macrophages
nanoconjugates
Nanotechnology - methods
Neoplasms - pathology
Neoplasms - therapy
Phagocytosis
Therapy
Tumors
antibodies
cancer
exosomes
nanoconjugates
immunotherapy
ISSN:1433-7851, 1521-3773, 1521-3773
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Exosomes hold great potential in therapeutic development. However, native exosomes usually induce insufficient effects in vivo and simply act as drug delivery vehicles. Herein, we synthesize responsive exosome nano‐bioconjugates for cancer therapy. Azide‐modified exosomes derived from M1 macrophages are conjugated with dibenzocyclooctyne‐modified antibodies of CD47 and SIRPα (aCD47 and aSIRPα) through pH‐sensitive linkers. After systemic administration, the nano‐bioconjugates can actively target tumors through the specific recognition between aCD47 and CD47 on the tumor cell surface. In the acidic tumor microenvironment, the benzoic‐imine bonds of the nano‐bioconjugates are cleaved to release aSIRPα and aCD47 that can, respectively, block SIRPα on macrophages and CD47, leading to abolished “don't eat me” signaling and improved phagocytosis of macrophages. Meanwhile, the native M1 exosomes effectively reprogram the macrophages from pro‐tumoral M2 to anti‐tumoral M1. Ok, take a bite: Responsive exosome nano‐bioconjugates were constructed by engineering M1 exosomes with aCD47 and aSIRPα linked with a pH‐sensitive bond. After systemic administration, the synergism of specific targeting by aCD47, blocking of “don't eat me” signaling by aCD47 and aSIRPα, and M2 reprogramming by M1 exosomes resulted in a potent anticancer effect.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1433-7851
1521-3773
1521-3773
DOI:10.1002/anie.201912524